List of Excipients in Branded Drug CAPRELSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	CELLULOSE, MICROCRYSTALLINE	2028-08-08
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	CROSPOVIDONE	2028-08-08
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	DIBASIC CALCIUM PHOSPHATE DIHYDRATE	2028-08-08
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	HYPROMELLOSE	2028-08-08
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	MAGNESIUM STEARATE	2028-08-08
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	POLYETHYLENE GLYCOL 300	2028-08-08
Genzyme Corporation	CAPRELSA	vandetanib	58468-7820	POVIDONE	2028-08-08

Caprelsa Excipient Strategy and Commercial Opportunities for Vandetanib

Last updated: August 28, 2026

Caprelsa contains vandetanib, a small-molecule tyrosine kinase inhibitor approved for symptomatic or progressive medullary thyroid cancer. Its commercial opportunity is primarily in generic tablets, differentiated oral liquids, pediatric and dysphagia-friendly presentations, and excipient optimization for stability and supply continuity. Because vandetanib is a small molecule rather than a biologic, biosimilar competition is not relevant; the principal threat is conventional generic entry through the ANDA pathway or reformulated products through a 505(b)(2) application.

What excipients are used in Caprelsa tablets?

The marketed Caprelsa tablets use a conventional immediate-release tablet platform with inorganic filler, superdisintegrants, film-coating polymers, lubricants, surfactant, and colorants.

Component	Reported function
Calcium hydrogen phosphate dihydrate	Diluent and compressibility aid
Microcrystalline cellulose	Diluent and dry-binder
Crospovidone	Superdisintegrant
Povidone	Binder
Hypromellose	Film-coating polymer
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting and dissolution aid
Titanium dioxide	Opacifier and colorant
Iron oxide	Tablet colorant

The inactive-ingredient profile is reported in the U.S. prescribing information and DailyMed product labeling. The 100 mg and 300 mg strengths use the same general immediate-release technology, with strength-specific tablet dimensions and color differences [1, 2].

What does the Caprelsa formulation imply for generic development?

The formulation is technically accessible to generic manufacturers. It does not depend on a complex delivery system, lipid carrier, modified-release matrix, device, or biologic manufacturing process. The main development issues are:

1. Matching dissolution across the relevant pH range.
2. Controlling tablet hardness without delaying disintegration.
3. Managing the low-dose-to-high-dose formulation ratio between 100 mg and 300 mg tablets.
4. Demonstrating chemical and physical stability.
5. Controlling exposure to moisture and light.
6. Preserving the tablet’s ability to disperse in water for patients unable to swallow tablets.

The reference product label instructs patients to disperse Caprelsa in noncarbonated water when needed. This use case creates a practical benchmark for generic products even if the proposed product remains a conventional tablet [1].

What commercial opportunities exist for Caprelsa excipient reformulation?

The strongest opportunities are oral liquids, dispersible tablets, and supply-chain improvements rather than minor changes to the existing tablet excipients.

Ready-to-use oral suspension

A commercially differentiated vandetanib oral suspension could target:

• Patients with dysphagia.
• Patients receiving treatment through a nasogastric or gastrostomy tube.
• Pediatric or adolescent patients in jurisdictions where pediatric use is authorized.
• Specialty pharmacies seeking simplified administration.
• Hospitals requiring standardized preparation rather than bedside tablet dispersion.

The current tablet can be dispersed in water, but that process is not equivalent to a commercially manufactured liquid. A ready-to-use suspension could improve dose uniformity, reduce preparation variability, and support administration through enteral tubes.

Potential excipient systems include:

• Aqueous suspending polymers such as hydroxypropyl cellulose or xanthan gum.
• Wetting agents compatible with vandetanib.
• Buffers selected to preserve chemical stability.
• Preservatives for multidose packaging.
• Chelating agents if trace-metal sensitivity is demonstrated.
• Sweeteners and flavors for oral acceptability.

The key development risk is not simply suspension uniformity. Vandetanib is associated with clinically important QT prolongation and other serious risks. Any liquid product must provide accurate dosing over the full in-use period, including the final doses in a bottle. A 505(b)(2) strategy may be more suitable than an ANDA if the product introduces a materially different dosage form, dosing device, preservative system, or administration method.

Dispersible or orally disintegrating tablets

A dispersible tablet could be positioned as a lower-complexity alternative to a suspension. The formulation would need to disintegrate rapidly without creating unacceptable grittiness, excessive foaming, or dose loss on the administration vessel.

Relevant excipient candidates include:

• Crospovidone or sodium starch glycolate for rapid disintegration.
• Mannitol or directly compressible sugars for mouthfeel.
• Low-substituted hydroxypropyl cellulose for wicking.
• Reduced lubricant concentrations to avoid dissolution delays.
• Taste-masking polymers or ion-exchange materials if palatability is a concern.

An orally disintegrating tablet is less attractive if vandetanib has a highly persistent unpleasant taste or if the label requires administration as a swallowed dose rather than buccal absorption. A dispersible tablet intended for water administration may have a clearer clinical use case.

Excipient substitution and supply continuity

A generic manufacturer may seek to replace sodium lauryl sulfate, colorants, or specific polymer grades because of:

• Supplier concentration.
• Nitrosamine or impurity concerns in the broader pharmaceutical supply chain.
• Regional excipient restrictions.
• Cost pressure.
• Changes in excipient availability.
• Manufacturing-site transfer requirements.

A substitution program should focus on function rather than nominal composition. The critical controls are dissolution, disintegration, content uniformity, assay, related substances, tablet friability, and stability.

How should a generic manufacturer select Caprelsa excipients?

A practical development strategy is to maintain the reference product’s release profile while reducing unnecessary formulation complexity.

Development objective	Preferred excipient strategy	Main risk
Conventional generic tablet	Retain calcium phosphate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate platform	Dissolution mismatch or scale-up variability
Sodium lauryl sulfate replacement	Use a lower-risk wetting system or optimize granulation and particle size	Reduced wetting and slower dissolution
Colorant reduction	Use a minimal-color or color-free film coat	Product identification and regulatory comparability
Dysphagia product	Develop dispersible tablet or suspension	Dose uniformity and stability
Enteral-tube administration	Use suspension with validated tube recovery	Adsorption, clogging, and dose loss
Pediatric presentation	Use a liquid or low-dose dispersible unit	Palatability and dosing accuracy
Global product	Design for regional excipient acceptability	Multiple filings and packaging configurations

The reference formulation contains both calcium hydrogen phosphate dihydrate and microcrystalline cellulose. That combination can support robust compression, but it requires attention to particle-size distribution and lubricant mixing. Over-lubrication with magnesium stearate can reduce tablet tensile strength and slow dissolution. Sodium lauryl sulfate may improve wetting but can create manufacturing and tolerability considerations.

What FDA regulatory pathway applies to a Caprelsa generic?

A conventional vandetanib tablet with the same strength, route, dosage form, and therapeutic conditions would generally be evaluated under the ANDA pathway, subject to FDA requirements for pharmaceutical equivalence and bioequivalence. A materially different oral liquid, dispersible product, or administration method may require a 505(b)(2) application rather than an ANDA [3].

ANDA opportunity

The ANDA route is most commercially attractive for:

• 100 mg immediate-release tablets.
• 300 mg immediate-release tablets.
• Excipients that differ only where the product remains pharmaceutically equivalent.
• A manufacturing process that reproduces the reference product’s performance.

The largest commercial advantage is lower clinical-development cost compared with a new drug application. The principal risk is timing relative to Orange Book patent listings, regulatory exclusivity, and Paragraph IV challenges.

505(b)(2) opportunity

A 505(b)(2) application may support:

• Ready-to-use oral suspension.
• Concentrated liquid for tube administration.
• Dispersible tablet.
• New dosing device.
• Alternative administration instructions.
• Reformulation addressing a documented clinical or pharmaceutical limitation.

A 505(b)(2) product can create a more differentiated commercial position, but it usually requires greater development work, including formulation-specific stability, dosing accuracy, in-use testing, compatibility, and potentially clinical bridging.

When does Caprelsa lose exclusivity?

Caprelsa’s U.S. orphan-drug exclusivity was tied to the 2011 approval for medullary thyroid cancer and ran for seven years, subject to the statutory orphan-exclusivity framework. That period did not create a permanent barrier to generic development. Patent protection and any listed regulatory exclusivity are separate questions [1, 4].

The commercial launch date for a generic depends on the live Orange Book listing, patent certifications, litigation, settlement terms, and any applicable pediatric or other exclusivity. A manufacturer should not infer launch freedom from the expiration of orphan exclusivity alone.

What is the Orange Book and Paragraph IV risk for Caprelsa?

The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with approved Caprelsa products. A generic applicant must review the current listing for:

• Vandetanib active-ingredient or composition claims.
• Method-of-use claims.
• Any listed formulation or dosage-form patents.
• Patent expiration dates.
• Pediatric exclusivity.
• Whether a listed patent has been delisted or remains relevant to the proposed label [5].

Paragraph IV risk is likely to center on method-of-use patents and any surviving formulation or composition claims rather than on the basic existence of vandetanib as a small molecule. The commercial value of a Paragraph IV filing depends on claim scope, prosecution history, patent-term adjustment, FDA listing status, and whether the proposed label would induce infringement.

A generic applicant should separate three issues:

1. Whether the patent is listed.
2. Whether the patent claims the proposed product or labeled use.
3. Whether the applicant can use a section viii statement to omit a patented indication from the label.

What method-of-use patents could affect vandetanib generic launch?

Vandetanib method-of-use claims may cover treatment of medullary thyroid cancer, patient-selection criteria, dosing schedules, or management of disease progression. These claims can remain commercially relevant even when compound or composition claims have expired.

A skinny-label strategy may reduce infringement exposure if the patented indication can be omitted while the remaining approved uses support a lawful generic label. That strategy requires careful analysis of:

• The exact FDA indication.
• The claim language.
• Prescribing behavior.
• Promotional restrictions.
• Induced-infringement precedent.
• The extent to which the protected use is inseparable from the approved indication.

For a rare oncology product, a narrow label may also reduce market access because specialists may expect the generic to carry the full indication.

Are biosimilars a risk for Caprelsa?

No. Caprelsa contains vandetanib, a chemically synthesized small molecule. Competition would arise through generic-drug pathways, not biosimilar pathways. The relevant competitors are therefore ANDA applicants, 505(b)(2) developers, specialty-pharmacy suppliers, and potentially compounding or hospital-prepared products where legally permitted.

What manufacturing and intellectual-property barriers affect vandetanib products?

The active pharmaceutical ingredient is not the only barrier. Commercial execution depends on:

• Reliable API sourcing.
• Control of vandetanib-related impurities.
• Occupational containment during powder handling.
• Low-dose blend uniformity for any reduced-strength presentation.
• Moisture and light protection.
• Film-coating consistency.
• Packaging that protects shelf life.
• Enteral-tube compatibility for liquid or dispersible products.
• Stability after dispersion or opening.

Excipient patents are unlikely to be the principal barrier for a standard Caprelsa generic. The stronger defensibility for a reformulated product would come from a combination of formulation claims, process controls, packaging, device claims, stability data, and a clinically relevant administration advantage.

A suspension with validated long-term in-use stability and enteral-tube recovery could support a more defensible 505(b)(2) position than a tablet with a minor excipient substitution. The commercial value would depend on whether payers, specialty pharmacies, and oncology practices recognize a measurable administration benefit.

How does Caprelsa compare with other targeted oncology drugs?

Attribute	Caprelsa	Typical oral oncology tablet	Commercial implication
Active ingredient	Vandetanib	Small-molecule kinase inhibitor	Generic pathway is available
Dosage form	Immediate-release tablet	Often tablet or capsule	Liquid and dispersible differentiation is possible
Disease area	Medullary thyroid cancer	Frequently broader oncology indications	Smaller addressable market
Administration challenge	Label-supported water dispersion	Varies by product	Supports dysphagia and tube-administration opportunity
Biosimilar exposure	None	None for small molecules	Generic competition is the relevant risk
Safety sensitivity	QT prolongation and serious adverse-event monitoring	Product-specific	Dosing accuracy is commercially important
Formulation complexity	Moderate	Low to high	Conventional tablets are easier to copy

Caprelsa’s smaller patient population limits the revenue available to a reformulation. The same factor can reduce the number of generic entrants, particularly where the product requires oncology-specialty distribution and pharmacovigilance capabilities.

What licensing opportunities exist for Caprelsa excipients and formulations?

The most credible licensing targets are:

• A stabilized vandetanib suspension platform.
• A dispersible tablet technology with validated dose recovery.
• A pediatric-friendly taste-masking system.
• An enteral-tube delivery platform.
• A global excipient-substitution package.
• A contract manufacturing arrangement with containment and oncology-product experience.

No excipient-specific license is established by the core FDA product label or European regulatory assessment. The likely licensing value would arise from proprietary formulation know-how, patents on the dosage form, manufacturing process, packaging, or device rather than from the use of standard excipients alone [1, 6].

What revenue exposure and generic launch scenarios should investors consider?

Caprelsa is an orphan oncology product, so revenue exposure depends more on price, duration of therapy, and specialty distribution than on large-volume prescription demand. Generic entry could produce several scenarios:

Scenario	Likely commercial effect
Single tablet generic	Price erosion with limited supply competition
Multiple ANDA entrants	Faster price compression and reduced branded share
Paragraph IV launch	Early generic entry risk and litigation expense
505(b)(2) oral liquid	Smaller but potentially higher-value niche
Dispersible tablet	Moderate differentiation, depending on payer treatment
Supply disruption at incumbent	Temporary value for alternate suppliers
Specialty-pharmacy partnership	Improved access for a formulation with administration advantages

The standard tablet is likely to face the greatest price pressure once legally available generics enter. A liquid or tube-compatible formulation could preserve margin if it solves a recognized administration problem and avoids direct substitution in all patients.

How strong is the Caprelsa excipient patent opportunity?

The excipient patent opportunity is moderate for a standard generic tablet and stronger for a differentiated dosage form.

A weak patent position would cover only routine use of known fillers, binders, disintegrants, or lubricants. Such claims face validity and obviousness challenges. A stronger position could combine:

• A defined vandetanib particle-size distribution.
• A specific dissolution profile.
• A stable suspension over a defined storage period.
• Validated tube recovery.
• A preservative system compatible with vandetanib.
• A packaging configuration that limits degradation.
• A manufacturing process that reduces a defined impurity.

The best commercial strategy is therefore to use excipient development to create a clinically useful product attribute, not merely to replace one conventional excipient with another.

Key Takeaways

• Caprelsa is an immediate-release vandetanib tablet with a conventional excipient platform.
• The main competition risk is generic entry, not biosimilar competition.
• Conventional 100 mg and 300 mg tablets are the clearest ANDA opportunity.
• Ready-to-use suspensions and dispersible tablets offer greater differentiation but may require a 505(b)(2) pathway.
• The existing water-dispersion instruction supports development of a standardized oral-liquid or enteral-tube product.
• QT-related safety concerns make dose uniformity, stability, and administration accuracy central to product development.
• Standard excipient substitutions have limited standalone patent value.
• Stronger commercial protection could come from formulation, process, packaging, and device claims tied to a measurable administration benefit.
• Orange Book listings, patent certifications, litigation, and settlement terms determine the practical generic launch window.

FAQs

Can vandetanib be formulated as an oral suspension?

Yes. A suspension is technically feasible, but the product would require validated content uniformity, sedimentation control, redispersibility, chemical stability, preservative performance, and dose recovery through any intended enteral tube.

Is a Caprelsa liquid automatically substitutable for the tablet?

No. A liquid with different concentration, excipients, dosing instructions, or administration characteristics may require a separate regulatory pathway and may not receive automatic pharmacy substitution treatment.

Which excipient is most important for Caprelsa dissolution?

Sodium lauryl sulfate may contribute to wetting, while crospovidone supports rapid disintegration. Particle size, compression force, lubricant mixing, and granulation conditions can be equally important.

Does a pediatric vandetanib product have a clear commercial opportunity?

The opportunity is limited by the rare disease population but may be meaningful where children or patients with severe dysphagia require accurate low-volume dosing. Palatability and dose flexibility would determine adoption.

Can a reformulated vandetanib product receive new patent protection?

Yes, if the formulation or manufacturing process contains a novel and nonobvious feature with a defensible technical effect, such as improved stability, tube recovery, dose uniformity, or clinically useful administration performance.

References

1. U.S. Food and Drug Administration. (2011). Caprelsa (vandetanib) prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Caprelsa- vandetanib tablet, film coated.
3. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. European Medicines Agency. (2012). Caprelsa: EPAR - product information.